Annual CFO
-$21.58 M
+$2.10 M+8.87%
31 December 2023
Summary:
Evogene annual cash flow from operations is currently -$21.58 million, with the most recent change of +$2.10 million (+8.87%) on 31 December 2023. During the last 3 years, it has fallen by -$2.06 million (-10.57%). EVGN annual CFO is now -1111.58% below its all-time high of $2.13 million, reached on 31 December 2011.EVGN Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$4.93 M
+$527.00 K+9.66%
30 September 2024
Summary:
Evogene quarterly cash flow from operations is currently -$4.93 million, with the most recent change of +$527.00 thousand (+9.66%) on 30 September 2024. Over the past year, it has dropped by -$611.00 thousand (-14.15%). EVGN quarterly CFO is now -889.56% below its all-time high of -$498.00 thousand, reached on 31 December 2013.EVGN Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$20.42 M
-$611.00 K-3.08%
30 September 2024
Summary:
Evogene TTM cash flow from operations is currently -$20.42 million, with the most recent change of -$611.00 thousand (-3.08%) on 30 September 2024. Over the past year, it has dropped by -$2.51 million (-14.01%). EVGN TTM CFO is now -632.62% below its all-time high of -$2.79 million, reached on 31 March 2013.EVGN TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EVGN Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +8.9% | -14.2% | -14.0% |
| 3 y3 years | -10.6% | +15.2% | +13.1% |
| 5 y5 years | -42.3% | -35.8% | -28.0% |
EVGN Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -10.6% | +12.7% | -118.3% | +39.0% | -14.0% | +30.8% |
| 5 y | 5 years | -42.3% | +12.7% | -118.3% | +39.0% | -28.0% | +30.8% |
| alltime | all time | -1111.6% | +12.7% | -889.6% | +39.0% | -632.6% | +30.8% |
Evogene Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$4.93 M(-9.7%) | -$20.42 M(+3.1%) |
| June 2024 | - | -$5.46 M(+32.7%) | -$19.81 M(+1.9%) |
| Mar 2024 | - | -$4.11 M(-30.6%) | -$19.44 M(-9.9%) |
| Dec 2023 | -$21.58 M(-8.9%) | -$5.92 M(+37.2%) | -$21.58 M(+20.5%) |
| Sept 2023 | - | -$4.32 M(-15.2%) | -$17.91 M(-13.3%) |
| June 2023 | - | -$5.09 M(-18.5%) | -$20.65 M(-7.1%) |
| Mar 2023 | - | -$6.24 M(+176.7%) | -$22.21 M(-6.2%) |
| Dec 2022 | -$23.68 M(-4.2%) | -$2.26 M(-68.0%) | -$23.68 M(-19.7%) |
| Sept 2022 | - | -$7.06 M(+6.0%) | -$29.50 M(+4.4%) |
| June 2022 | - | -$6.66 M(-13.6%) | -$28.26 M(+1.9%) |
| Mar 2022 | - | -$7.71 M(-4.6%) | -$27.73 M(+12.2%) |
| Dec 2021 | -$24.72 M(+26.7%) | -$8.08 M(+39.1%) | -$24.72 M(+5.2%) |
| Sept 2021 | - | -$5.81 M(-5.3%) | -$23.50 M(+6.4%) |
| June 2021 | - | -$6.13 M(+30.8%) | -$22.09 M(+17.9%) |
| Mar 2021 | - | -$4.69 M(-31.8%) | -$18.73 M(-4.0%) |
| Dec 2020 | -$19.51 M(+10.5%) | -$6.87 M(+56.4%) | -$19.51 M(+12.8%) |
| Sept 2020 | - | -$4.39 M(+58.3%) | -$17.30 M(+4.6%) |
| June 2020 | - | -$2.77 M(-49.3%) | -$16.54 M(-7.0%) |
| Mar 2020 | - | -$5.48 M(+17.5%) | -$17.78 M(+0.7%) |
| Dec 2019 | -$17.67 M(+16.5%) | -$4.66 M(+28.4%) | -$17.67 M(+10.7%) |
| Sept 2019 | - | -$3.63 M(-9.7%) | -$15.95 M(-2.2%) |
| June 2019 | - | -$4.02 M(-25.0%) | -$16.32 M(+4.7%) |
| Mar 2019 | - | -$5.36 M(+81.8%) | -$15.59 M(+2.8%) |
| Dec 2018 | -$15.16 M | -$2.95 M(-26.2%) | -$15.16 M(-3.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$3.99 M(+21.5%) | -$15.78 M(+3.9%) |
| June 2018 | - | -$3.29 M(-33.3%) | -$15.19 M(-5.0%) |
| Mar 2018 | - | -$4.93 M(+38.3%) | -$16.00 M(+0.4%) |
| Dec 2017 | -$15.93 M(+36.2%) | -$3.57 M(+4.7%) | -$15.93 M(-4.0%) |
| Sept 2017 | - | -$3.41 M(-16.8%) | -$16.59 M(+1.6%) |
| June 2017 | - | -$4.09 M(-15.9%) | -$16.33 M(+12.6%) |
| Mar 2017 | - | -$4.87 M(+15.0%) | -$14.50 M(+24.0%) |
| Dec 2016 | -$11.69 M(-5.8%) | -$4.23 M(+34.9%) | -$11.69 M(-1.6%) |
| Sept 2016 | - | -$3.14 M(+38.3%) | -$11.88 M(+4.6%) |
| June 2016 | - | -$2.27 M(+10.5%) | -$11.36 M(-4.5%) |
| Mar 2016 | - | -$2.05 M(-53.5%) | -$11.89 M(-4.2%) |
| Dec 2015 | -$12.41 M(+39.5%) | -$4.42 M(+69.1%) | -$12.41 M(+29.7%) |
| Sept 2015 | - | -$2.62 M(-6.6%) | -$9.57 M(+6.4%) |
| June 2015 | - | -$2.80 M(+8.8%) | -$8.99 M(+9.1%) |
| Mar 2015 | - | -$2.57 M(+62.6%) | -$8.24 M(-7.3%) |
| Dec 2014 | -$8.89 M(+68.8%) | -$1.58 M(-22.5%) | -$8.89 M(+13.9%) |
| Sept 2014 | - | -$2.04 M(-0.3%) | -$7.81 M(+7.9%) |
| June 2014 | - | -$2.05 M(-36.5%) | -$7.24 M(+26.9%) |
| Mar 2014 | - | -$3.22 M(+547.2%) | -$5.71 M(+8.3%) |
| Dec 2013 | -$5.27 M(+179.1%) | -$498.00 K(-66.1%) | -$5.27 M(+10.4%) |
| Sept 2013 | - | -$1.47 M(+185.4%) | -$4.77 M(+44.5%) |
| June 2013 | - | -$515.00 K(-81.5%) | -$3.30 M(+18.5%) |
| Mar 2013 | - | -$2.79 M | -$2.79 M |
| Dec 2012 | -$1.89 M(-188.5%) | - | - |
| Dec 2011 | $2.13 M | - | - |
FAQ
- What is Evogene annual cash flow from operations?
- What is the all time high annual CFO for Evogene?
- What is Evogene annual CFO year-on-year change?
- What is Evogene quarterly cash flow from operations?
- What is the all time high quarterly CFO for Evogene?
- What is Evogene quarterly CFO year-on-year change?
- What is Evogene TTM cash flow from operations?
- What is the all time high TTM CFO for Evogene?
- What is Evogene TTM CFO year-on-year change?
What is Evogene annual cash flow from operations?
The current annual CFO of EVGN is -$21.58 M
What is the all time high annual CFO for Evogene?
Evogene all-time high annual cash flow from operations is $2.13 M
What is Evogene annual CFO year-on-year change?
Over the past year, EVGN annual cash flow from operations has changed by +$2.10 M (+8.87%)
What is Evogene quarterly cash flow from operations?
The current quarterly CFO of EVGN is -$4.93 M
What is the all time high quarterly CFO for Evogene?
Evogene all-time high quarterly cash flow from operations is -$498.00 K
What is Evogene quarterly CFO year-on-year change?
Over the past year, EVGN quarterly cash flow from operations has changed by -$611.00 K (-14.15%)
What is Evogene TTM cash flow from operations?
The current TTM CFO of EVGN is -$20.42 M
What is the all time high TTM CFO for Evogene?
Evogene all-time high TTM cash flow from operations is -$2.79 M
What is Evogene TTM CFO year-on-year change?
Over the past year, EVGN TTM cash flow from operations has changed by -$2.51 M (-14.01%)